{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:16:26Z","timestamp":1789748186282,"version":"4.0.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,8,6]],"date-time":"2021-08-06T00:00:00Z","timestamp":1628208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,6]],"date-time":"2021-08-06T00:00:00Z","timestamp":1628208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Immunol Res"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s12026-021-09219-y","type":"journal-article","created":{"date-parts":[[2021,8,6]],"date-time":"2021-08-06T05:02:38Z","timestamp":1628226158000},"page":"457-460","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["COVID-19, Ebola virus disease, and Nipah virus infection reclassification as novel acute immune dysrhythmia syndrome (n-AIDS): potential crucial role for immunomodulators"],"prefix":"10.1007","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6290-6025","authenticated-orcid":false,"given":"Mina T.","family":"Kelleni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,6]]},"reference":[{"issue":"3","key":"9219_CR1","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/0167-5699(93)90208-3","volume":"14","author":"M Clerici","year":"1993","unstructured":"Clerici M, Shearer GM. A TH1\u2192TH2 switch is a critical step in the etiology of HIV infection. Immunol Today. 1993;14(3):107\u201311.","journal-title":"Immunol Today"},{"key":"9219_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.02033","author":"Y-Y Zhang","year":"2020","unstructured":"Zhang Y-Y, et al. The comparative immunological characteristics of SARS-CoV, MERS-CoV, and SARS-CoV-2 coronavirus infections. Front Immunol. 2020. https:\/\/doi.org\/10.3389\/fimmu.2020.02033.","journal-title":"Front Immunol"},{"key":"9219_CR3","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.4049\/jimmunol.2001034","volume":"206","author":"J Rupp","year":"2021","unstructured":"Rupp J, et al. T cell phenotyping in individuals hospitalized with COVID-19. J Immunol. 2021;206:1478.","journal-title":"J Immunol"},{"issue":"5","key":"9219_CR4","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41423-020-0402-2","volume":"17","author":"M Zheng","year":"2020","unstructured":"Zheng M, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. 2020;17(5):533\u20135.","journal-title":"Cell Mol Immunol"},{"key":"9219_CR5","doi-asserted-by":"publisher","first-page":"155439","DOI":"10.1016\/j.cyto.2021.155439","volume":"140","author":"R Sami","year":"2021","unstructured":"Sami R, et al. Characterizing the immune responses of those who survived or succumbed to COVID-19: can immunological signatures predict outcome? Cytokine. 2021;140:155439.","journal-title":"Cytokine"},{"issue":"3","key":"9219_CR6","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1007\/s43465-020-00121-7","volume":"54","author":"A Gupta","year":"2020","unstructured":"Gupta A. Is immuno-modulation the key to COVID-19 pandemic? Indian J Orthopaedics. 2020;54(3):394\u20137.","journal-title":"Indian J Orthopaedics"},{"key":"9219_CR7","first-page":"270","volume":"587","author":"J Neidleman","year":"2021","unstructured":"Neidleman J, et al. Distinctive features of SARS-CoV-2-specific T cells predict recovery from severe COVID-19. MedRxiv. 2021;587:270.","journal-title":"MedRxiv"},{"key":"9219_CR8","doi-asserted-by":"publisher","first-page":"198171","DOI":"10.1016\/j.virusres.2020.198171","volume":"289","author":"AC Gadotti","year":"2020","unstructured":"Gadotti AC, et al. IFN-\u03b3 is an independent risk factor associated with mortality in patients with moderate and severe COVID-19 infection. Virus Res. 2020;289:198171\u2013198171.","journal-title":"Virus Res"},{"issue":"1","key":"9219_CR9","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41590-020-00840-x","volume":"22","author":"I-E Galani","year":"2021","unstructured":"Galani I-E, et al. Untuned antiviral immunity in COVID-19 revealed by temporal type I\/III interferon patterns and flu comparison. Nat Immunol. 2021;22(1):32\u201340.","journal-title":"Nat Immunol"},{"issue":"12","key":"9219_CR10","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.3390\/v12121433","volume":"12","author":"L Lopez","year":"2020","unstructured":"Lopez L, et al. Dysregulated interferon response underlying severe COVID-19. Viruses. 2020;12(12):1433.","journal-title":"Viruses"},{"key":"9219_CR11","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2021.1939683","author":"MT Kelleni","year":"2021","unstructured":"Kelleni MT. NSAIDs\/nitazoxanide\/azithromycin repurposed for COVID-19: potential mitigation of the cytokine storm interleukin-6 amplifier via immunomodulatory effects. Expert Rev Anti Infect Ther. 2021. https:\/\/doi.org\/10.1080\/14787210.2021.1939683.","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"6515","key":"9219_CR12","doi-asserted-by":"publisher","first-page":"eabd4585","DOI":"10.1126\/science.abd4585","volume":"370","author":"P Bastard","year":"2020","unstructured":"Bastard P, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370(6515):eabd4585.","journal-title":"Science"},{"key":"9219_CR13","doi-asserted-by":"publisher","first-page":"145325","DOI":"10.1016\/j.gene.2020.145325","volume":"768","author":"J Luo","year":"2021","unstructured":"Luo J, et al. The potential involvement of JAK-STAT signaling pathway in the COVID-19 infection assisted by ACE2. Gene. 2021;768:145325.","journal-title":"Gene"},{"key":"9219_CR14","doi-asserted-by":"publisher","DOI":"10.22541\/au.162126670.06196092\/v2","author":"M Kelleni","year":"2021","unstructured":"Kelleni M. ACE2 Polymorphisms reflected on the immune and apelinergic peptide systems: potential COVID-19 tools for risk stratification and therapy. Authorea (Preprint). 2021. https:\/\/doi.org\/10.22541\/au.162126670.06196092\/v2.","journal-title":"Authorea (Preprint)"},{"key":"9219_CR15","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41586-020-03065-y","volume":"591","author":"E Pairo-Castineira","year":"2020","unstructured":"Pairo-Castineira E, et al. Genetic mechanisms of critical illness in Covid-19. Nature. 2020;591:92\u20138.","journal-title":"Nature"},{"key":"9219_CR16","doi-asserted-by":"publisher","DOI":"10.22541\/au.162126663.38675715\/v2","author":"M Kelleni","year":"2021","unstructured":"Kelleni M. NSAIDs Immunomodulation in COVID-19 might inhibit SARS CoV-2 ORF proteins induced caspase activation, necroptosis and endoplasmic reticulum stress. Authorea (Preprint). 2021. https:\/\/doi.org\/10.22541\/au.162126663.38675715\/v2.","journal-title":"Authorea (Preprint)"},{"key":"9219_CR17","doi-asserted-by":"publisher","first-page":"2000763","DOI":"10.1183\/13993003.00763-2020","volume":"56","author":"B Lou","year":"2020","unstructured":"Lou B, et al. Serology characteristics of SARS-CoV-2 infection since exposure and post symptom onset. Eur Respir J. 2020;56:2000763.","journal-title":"Eur Respir J"},{"key":"9219_CR18","doi-asserted-by":"publisher","DOI":"10.1101\/2021.01.21.21249176","author":"N Bhadelia","year":"2021","unstructured":"Bhadelia N, et al. Distinct autoimmune antibody signatures between hospitalized acute COVID-19 patients, SARS-CoV-2 convalescent individuals, and unexposed pre-pandemic controls. MedRxiv. 2021. https:\/\/doi.org\/10.1101\/2021.01.21.21249176.","journal-title":"MedRxiv"},{"key":"9219_CR19","doi-asserted-by":"publisher","first-page":"110345","DOI":"10.1016\/j.mehy.2020.110345","volume":"145","author":"CA Ca\u00f1as","year":"2020","unstructured":"Ca\u00f1as CA. The triggering of post-COVID-19 autoimmunity phenomena could be associated with both transient immunosuppression and an inappropriate form of immune reconstitution in susceptible individuals. Med Hypotheses. 2020;145:110345.","journal-title":"Med Hypotheses"},{"issue":"5","key":"9219_CR20","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.cell.2020.04.026","volume":"181","author":"D Blanco-Melo","year":"2020","unstructured":"Blanco-Melo D, et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell. 2020;181(5):1036\u201345.e1039.","journal-title":"Cell"},{"key":"9219_CR21","doi-asserted-by":"publisher","DOI":"10.22541\/au.162126698.87303239\/v2","author":"M Kelleni","year":"2021","unstructured":"Kelleni M. SARS CoV-2 might exploit cells of the innate immune system to induce the novel acute immune dysrhythmic syndrome (n-AIDS) and para COVID-19 syndrome: a case report. Authorea (Preprint). 2021. https:\/\/doi.org\/10.22541\/au.162126698.87303239\/v2.","journal-title":"Authorea (Preprint)"},{"key":"9219_CR22","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ijid.2020.10.012","volume":"102","author":"H Pietsch","year":"2021","unstructured":"Pietsch H, et al. Proof of SARS-CoV-2 genomes in endomyocardial biopsy with latency after acute infection. Int J Infect Dis. 2021;102:70\u20132.","journal-title":"Int J Infect Dis"},{"issue":"11","key":"9219_CR23","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1038\/s41582-020-0398-3","volume":"16","author":"A Pezzini","year":"2020","unstructured":"Pezzini A, Padovani A. Lifting the mask on neurological manifestations of COVID-19. Nat Rev Neurol. 2020;16(11):636\u201344.","journal-title":"Nat Rev Neurol"},{"key":"9219_CR24","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/S2215-0366(21)00084-5","volume":"8","author":"M Taquet","year":"2021","unstructured":"Taquet M, et al. 6-month neurological and psychiatric outcomes in survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry. 2021;8:416\u201327.","journal-title":"Lancet Psychiatry"},{"key":"9219_CR25","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.idnow.2021.01.005","volume":"51","author":"A Simonnet","year":"2021","unstructured":"Simonnet A, et al. High incidence of Epstein-Barr virus, cytomegalovirus, and human-herpes virus-6 reactivations in critically ill patients with COVID-19. Infect Dis Now. 2021;51:296.","journal-title":"Infect Dis Now"},{"issue":"5","key":"9219_CR26","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1002\/ejhf.1828","volume":"22","author":"G Tavazzi","year":"2020","unstructured":"Tavazzi G, et al. Myocardial localization of coronavirus in COVID-19 cardiogenic shock. Eur J Heart Fail. 2020;22(5):911\u20135.","journal-title":"Eur J Heart Fail"},{"key":"9219_CR27","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.cellimm.2018.02.001","volume":"330","author":"M Liegeois","year":"2018","unstructured":"Liegeois M, et al. The interstitial macrophage: a long-neglected piece in the puzzle of lung immunity. Cell Immunol. 2018;330:91\u20136.","journal-title":"Cell Immunol"},{"issue":"8","key":"9219_CR28","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1038\/cdd.2015.67","volume":"22","author":"L Falasca","year":"2015","unstructured":"Falasca L, et al. Molecular mechanisms of Ebola virus pathogenesis: focus on cell death. Cell Death Differ. 2015;22(8):1250\u20139.","journal-title":"Cell Death Differ"},{"issue":"1","key":"9219_CR29","doi-asserted-by":"publisher","first-page":"3730","DOI":"10.1038\/s41467-020-17489-7","volume":"11","author":"A Wiedemann","year":"2020","unstructured":"Wiedemann A, et al. Long-lasting severe immune dysfunction in Ebola virus disease survivors. Nat Commun. 2020;11(1):3730.","journal-title":"Nat Commun"},{"issue":"4","key":"9219_CR30","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3390\/v11040373","volume":"11","author":"F Colavita","year":"2019","unstructured":"Colavita F, et al. Inflammatory and humoral immune response during Ebola virus infection in survivor and fatal cases occurred in Sierra Leone during the 2014\u20132016 outbreak in West Africa. Viruses. 2019;11(4):373.","journal-title":"Viruses"},{"key":"9219_CR31","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.19975.1","author":"R Pelissier","year":"2019","unstructured":"Pelissier R, et al. Recent advances in the understanding of Nipah virus immunopathogenesis and anti-viral approaches. F1000Research. 2019. https:\/\/doi.org\/10.12688\/f1000research.19975.1.","journal-title":"F1000Research"},{"issue":"1","key":"9219_CR32","doi-asserted-by":"publisher","first-page":"7483","DOI":"10.1038\/ncomms8483","volume":"6","author":"BA Satterfield","year":"2015","unstructured":"Satterfield BA, et al. The immunomodulating V and W proteins of Nipah virus determine disease course. Nat Commun. 2015;6(1):7483.","journal-title":"Nat Commun"},{"issue":"9","key":"9219_CR33","first-page":"1635","volume":"157","author":"J Prescott","year":"2012","unstructured":"Prescott J, et al. The immune response to Nipah virus infection. Adv Virol. 2012;157(9):1635\u201341.","journal-title":"Adv Virol"},{"key":"9219_CR34","doi-asserted-by":"publisher","first-page":"110982","DOI":"10.1016\/j.biopha.2020.110982","volume":"133","author":"MT Kelleni","year":"2021","unstructured":"Kelleni MT. Early use of non-steroidal anti-inflammatory drugs in COVID-19 might reverse pathogenesis, prevent complications and improve clinical outcomes. Biomed Pharmacother. 2021;133:110982.","journal-title":"Biomed Pharmacother"},{"key":"9219_CR35","first-page":"104583","volume":"85","author":"MA Saleemi","year":"2020","unstructured":"Saleemi MA, et al. Emergence and molecular mechanisms of SARS-CoV-2 and HIV to target host cells and potential therapeutics. Infect Genet Evol J Mol Epidemiol Evol Genet Infect Dis. 2020;85:104583\u2013104583.","journal-title":"Infect Genet Evol J Mol Epidemiol Evol Genet Infect Dis"},{"issue":"4","key":"9219_CR36","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1111\/tbed.13594","volume":"67","author":"K Roe","year":"2020","unstructured":"Roe K. Explanation for COVID-19 infection neurological damage and reactivations. Transbound Emerg Dis. 2020;67(4):1414\u20135.","journal-title":"Transbound Emerg Dis"},{"key":"9219_CR37","doi-asserted-by":"publisher","DOI":"10.22541\/au.162126601.15715282\/v5","author":"M Kelleni","year":"2021","unstructured":"Kelleni M. NSAIDs\/nitazoxanide\/azithromycin immunomodulatory protocol used in adults, geriatric, pediatric, pregnant, and immunocompromised COVID-19 patients: a prospective observational study and case-series. Authorea (Preprint). 2021. https:\/\/doi.org\/10.22541\/au.162126601.15715282\/v5.","journal-title":"Authorea (Preprint)"},{"issue":"3","key":"9219_CR38","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s40506-017-0130-z","volume":"9","author":"SL Bixler","year":"2017","unstructured":"Bixler SL, et al. Discovering drugs for the treatment of Ebola virus. Curr Treat Options Infect Dis. 2017;9(3):299\u2013317.","journal-title":"Curr Treat Options Infect Dis"}],"container-title":["Immunologic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-021-09219-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12026-021-09219-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-021-09219-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T06:13:34Z","timestamp":1631600014000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12026-021-09219-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,6]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["9219"],"URL":"https:\/\/doi.org\/10.1007\/s12026-021-09219-y","relation":{},"ISSN":["0257-277X","1559-0755"],"issn-type":[{"value":"0257-277X","type":"print"},{"value":"1559-0755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,6]]},"assertion":[{"value":"18 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author declares that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}